Neonatal screening for severe combined immune deficiency

Jennifer M Puck1

  • 1Department of Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, California 94143-0519, USA. puckj@peds.ucsf.edu

Insights

Newborn screening for severe combined immunodeficiency (SCID) is crucial for early detection and treatment. Advances in screening methods, like T cell receptor excision circles, are paving the way for pilot trials.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Severe combined immunodeficiency (SCID) is a serious genetic disorder affecting the immune system.
  • Early diagnosis and treatment are critical for improving outcomes in SCID patients.

Purpose of the Study:

  • To review the rationale for including SCID in newborn screening programs.
  • To outline current advancements and challenges in universal SCID screening.

Main Methods:

  • Review of existing literature on SCID screening.
  • Evaluation of T cell receptor excision circles (TRECs) as a screening biomarker.
  • Discussion of proposed and emerging screening methodologies.

Main Results:

  • SCID is treatable with hematopoietic stem cell transplantation, with outcomes improving significantly with early intervention.
  • Universal newborn screening can facilitate prompt diagnosis and timely treatment.
  • TREC quantitation on dried blood spots is a viable screening method, with other tests under evaluation.

Conclusions:

  • Newborn screening for SCID is progressing towards implementation in pilot programs.
  • Successful screening requires integrated systems for testing, diagnosis, treatment, and outcome tracking.
Abstract